Feasibility
Studies currently in Feasibility
Embedded Files
Last content update - 27th April 2026
Please contact the Cancer Research Team for more information
All Specialties
No trials currently in feasibility
No trials currently in feasibility
BLADDER
No trials currently in feasibility
No trials currently in feasibility
BREAST
No trials currently in feasibility
No trials currently in feasibility
COLORECTAL
No trials currently in feasibility
No trials currently in feasibility
GYNAE
MK2870-022
MK2870-022
Specialty: Gynae
PI: Prof. Dennis Hadjiyiannakis
CPMS No: 68839
Estimated Opening: April 2026
Description: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
OVACT
OVACT
Specialty: Gynae
PI: Prof. Dennis Hadjiyiannakis
CPMS No: 72651
Estimated Opening: June 2026
Description: A Phase I/Ib, Multi-centre, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of Cryptivax-1001, a mRNA Lipid Nanoparticle Therapeutic Cancer Vaccine, in Participants with FIGO Stage III–IV High-Grade Serous or Predominantly Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Following Optimal Primary/Interval Debulking Surgery and First-Line Platinum-Based Chemotherapy (OVACT Study)
Head & Neck
No trials currently in feasibility
No trials currently in feasibility
Lung
BNT324-01
BNT324-01
Specialty: Lung
PI: Dr Sin Lau
CPMS No: 66899
Estimated Opening: May/June 2026
Description: A Phase Ib/II, multi-site, open-label, three-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
Multiple Specialties
CANHEAR
CANHEAR
Specialty: Multiple
PI: n/a (PIC site)
IRAS No: 355684
Estimated Opening: Summer 2026
Description: Chemotherapy-Induced Hearing Loss and Health Inequality
PROSTATE
ELIPSE
ELIPSE
Speciality: Prostate
PI: Mr Michal Smolski
CPMS No: 63289
Estimated Opening: TBC 2026
Description: A randomised controlled trial comparing the clinical and cost-effectiveness of lymph node removal in patients undergoing curative surgery for localised high-risk Prostate Cancer.
RADIOTHERAPY
No trials currently in feasibility
No trials currently in feasibility
RENAL
Arcus_PEAK-1
Arcus_PEAK-1
Speciality: Renal
PI: Dr Natalie Charnley
CPMS No: 69744
Estimated Opening: April 2026
Description: Acrus Phase 3 ccRCC study: PEAK-1 will be a double-blind study investigating Casdatifan (AB521; HIF-2α inhibitor) in combination with cabozantinib (cabo) vs. placebo + cabo in patients with advanced or metastatic ccRCC whose cancer has progressed following prior anti-PD-1/PD-L1 therapy.
SKIN
No trials currently in feasibility
No trials currently in feasibility
Supportive and Palliative Care
No trials currently in feasibility
No trials currently in feasibility
Teens & Young Adults (TYA)
No trials currently in feasibility
No trials currently in feasibility
UPPER GI
Protieus
Protieus
Specialty: Upper GI
PI: Dr Catherine Mitchell
IRAS: 329646
Estimated Opening: May 2026
Description: A Randomised Phase 2 Trial Comparing Proton versus Photon Based Neoadjuvant Chemoradiation, followed by Adjuvant Immunotherapy, in Oesophageal Cancer.
Report abuse